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Concise Communication

Impact of preoperative chlorhexidine gluconate (CHG) application
methods on preoperative CHG skin concentration
Bobby G. Warren MPS1,2

, Alicia Nelson MPH, MSW1,2, David K. Warren MD, MPH3, Meghan A. Baker MD, ScD4,5,

Candace Miller MA3, Tracey Habrock BA3, Jahnavi Bongu MPH3, Abinav Gowda BA4, Jacob Johnson MD4,
Deverick J. Anderson MD, MPH1,2 and CDC Prevention Epicenters Program
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Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, 2Division of Infectious Diseases, Duke University Medical Center,
Durham, North Carolina, 3Division of Infectious Diseases, Washington University School of Medicine, Saint Louis, Missouri, 4Division of Infectious Disease,
Brigham and Women’s Hospital, Boston, Massachusetts and 5Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute,
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Abstract
Elective surgical patients routinely bathe with chlorhexidine gluconate (CHG) at home days prior to their procedures. However, the impact of
home CHG bathing on surgical site CHG concentration is unclear. We examined 3 different methods of applying CHG and hypothesized that
different application methods would impact resulting CHG skin concentration.
(Received 4 June 2020; accepted 24 August 2020)

Surgical site infections (SSIs) are the most common type of healthcareassociated infection (HAI) and lead to adverse patient outcomes.1 To
combat SSIs, the use of a skin antiseptic is recommended at least the
night before the surgical procedure.2 The antiseptic properties of
chlorhexidine gluconate (CHG) have been known since 1954, and
its safety and efficacy have been documented in a variety of settings.3,4
CHG activity is related to CHG skin concentration. Previous studies
have shown that a CHG skin concentration ≥18.75 μg/mL is inversely
associated with gram-positive microbial density on skin. Additionally,
the relative risk of skin contamination with Klebsiella pneumoniae
carbapenemase (KPC)–producing Enterobacteriaceae is decreased
by half in long-term acute-care hospital patients with CHG skin
concentrations ≥128 μg/mL.5,6
CHG no-rinse 2% CHG-impregnated cloths are more effective
than 4% CHG liquid formulae at reducing microbial density on
skin.7 Nonetheless, many elective surgical patients are provided
with the latter, possibly due to lower costs or ease of use.7-9 Few
studies have assessed the ability of 4% CHG liquid formula
application methods to reach published CHG skin concentration
thresholds with notable antimicrobial effectiveness. The objectives
of this study were to determine whether these three 4% CHG liquid
formula application methods differed in preoperative CHG skin
concentration and the proportion of samples that met one or both
key CHG skin concentration thresholds.
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Methods
We performed a multicenter, nonrandomized prospective cohort
study of patients undergoing elective hip, knee arthroplasty, spinal
fusion, or laminectomy at Duke University Health System Durham,
North Carolina, Barnes-Jewish Hospital Saint Louis, Missouri, and
Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Patients were recruited between December 2017 and December
2019 and were excluded if they were <18 years of age, undergoing
emergency surgery, or had a history of the same procedure in the prior
year. Patients were met during the preoperative period on the day of
surgery, informed consent was obtained, and surgical sites were
sampled using a sterile swab moistened with sterile water for 20 seconds
which was standardized at each study hospital. CHG concentrations
were determined using a semiquantitative colorimetric assay method.6
Patients were given different instructions, both written and verbal, during their preoperative appointment on how to bathe with
CHG prior to their surgery with no reminders. Instructions varied
by participating hospital as follows:
Institution/Strategy 1: During daily baths for 5 consecutive days
before and on the day of surgery, do the following steps: (1) shower
normally; (2) apply ¼ cup of 4% CHG Scrub Care soap from the
neck down with a clean washcloth; (3) allow the soap to sit for 2
minutes; and (4) rinse thoroughly and do not wash with any other
soap or cleanser.
Institution/Strategy 2: During daily baths the night before and
day of surgery, do the following steps: (1) shower normally; (2)
moisten the 4% CHG impregnated scrub brush and scrub from
the neck down with the sponge side of the soap pad; (3) let the soap
sit for 3–5 minutes; and (4) rinse thoroughly and do not wash with
any other soap or cleanser.
Institution/Strategy 3: During daily baths for 3 days prior to
surgery, do the following steps: (1) shower normally; (2) wash with
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Table 1. Clinical and Demographic Characteristics
Characteristic
Age, median y (IQR)
Sex, female

Total
(N = 139), No. (%)

Institution/Strategy 1
(N = 35), No. (%)

Institution/Strategy 2
(N = 73), No. (%)

Institution/Strategy 3
(N = 31), No. (%)

65 (60–72)

64 (53–71)

65 (60–74)

66 (60–72)

.27, .88, .37

77 (55)

20 (57)

41 (56)

16 (52)

.92, .67, .65

114 (82)

29 (83)

59 (81)

26 (84)

22 (16)

6 (17)

13 (18)

3 (10)

3 (2)

0 (0)

1 (1)

2 (6)

137 (99)

35 (100)

72 (99)

2 (1)

0 (0)

1 (1)

.87, .23, .57

Race
White
African American
Asian

.60, .52, .91

Ethnicity
Non-Hispanic
Hispanic

30 (97)
1 (3)
.71, .77, .22

Pre-existing skin conditions
Total
Eczema

P Value,
1v2, 2v3, 1v3

25 (18)

9 (26)

7 (10)

9 (29)

9 (6)

2 (6)

3 (4)

4 (13)

Psoriasis

1 (1)

1 (3)

0 (0)

0 (0)

Skin cancer

4 (3)

0 (20)

1 (1)

3 (10)

Other

12 (9)

7 (11)

3 (5)

2 (13)

Immunocompromised

12 (9)

4 (11)

4 (5)

4 (13)

Tobacco

10 (7)

1 (3)

5 (7)

4 (13)

.27, .19, .85
.40, .32, .12
<.01, .02, <.01

Procedure type
Hip prosthesis

42 (30)

6 (17)

20 (27)

16 (52)

Knee prosthesis

45 (32)

0 (0)

30 (41)

15 (48)

Laminectomy

10 (7)

4 (11)

6 (8)

0 (0)

Spinal fusion

42 (30)

25 (71)

17 (23)

0 (0)

Note. IQR, interquartile range.

4% CHG body wash; (3) allow body wash to sit for 1 minute; and
(4) rinse thoroughly and do not wash with any other soap or
cleanser.
Study data were collected, managed, and shared between institutions using REDCap electronic data capture hosted at Duke
University. The Mann-Whitney U test was used to compare
median CHG skin concentration and age, the Z-score test was used
to compare proportions of patients who met CHG skin concentration thresholds, and χ2 analysis was used for categorical variables.
A P value of 0.05 was considered significant; all statistical tests were
2-tailed; and all testing was completed using R software (R
Foundation for Statistical Computing, Vienna, Austria). This study
was approved by the institutional review boards of all participating sites.
Results
In total, 150 patients were enrolled between December 2017 and
December 2019; 11 patients did not have a CHG swab collected
and were excluded. Of the 139 remaining patients, 35 (25%) were
instructed to follow strategy 1 (6 days), 73 (53%) followed strategy
2 (2 days), and 31 (22%) followed strategy 3 (3 days). Of these 139
participants, 77 (55%) were female; the median age of the entire
cohort was 65 years (interquartile range [IQR], 60–72); and 114
(82%) were of white race. In general, the patients in each group

were similar, though a higher proportion of patients undergoing
knee arthroplasty followed strategies 2 and 3 and a lower proportion of patients undergoing laminectomy and spinal fusion
followed strategy 3 (Table 1).
Patients who were instructed to apply 4% CHG for 2 days had a
median CHG skin concentration of 78.1 μg/mL (IQR, 39.1–156.3);
those who applied CHG for 3 days had a median CHG concentration of 78.1 μg/mL (IQR, 39.1–156.3); and those who applied CHG
for 6 days had a median CHG concentration of 156.3 μg/mL (IQR,
78.1–312.5) (Fig. 1). There was no significant difference between
CHG skin concentrations for 2- and 3-day application methods;
however, both were significantly less than the 6-day application
method (P = .002 and 0.01, respectively).
Similar trends were identified related to each strategies ability
to reach important skin thresholds. Strategy 1 (6 days) achieved
the skin concentration threshold required for reduction of
gram-positive microbial density in 97% of patients and the skin
concentration threshold required for reduction of KPC-producing
Enterobacteriaceae in 60% of patients. Strategy 2 (3 days) achieved
these thresholds in 94% and 32% of patients, and strategy 3 (2 days)
achieved these thresholds in 86% and 28% of patients. There was
no statistical difference in the proportion of samples that met the
≥18.75 μg/mL threshold among the 3 CHG application methods;
however, strategy 1 met the ≥128 μg/mL threshold at significantly
higher proportions than the 2- and 3-day applications (P = .03 and
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Finally, patient compliance was monitored by participant verbal
reporting but was not confirmable.
In conclusion, our study supports the theoretical benefit of
certain strategies for preoperative bathing strategies. Repeated
CHG bathing was associated with higher preoperative CHG skin
concentrations. Indeed, improved application strategies for CHG
bathing may be needed to fully demonstrate this intervention as
an evidence-based approach. Subsequent trials to determine the
best methods for pre-operative CHG application should focus
on strategies that optimize preoperative CHG skin concentration.
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Fig. 1. Chlorhexidine gluconate (CHG) skin concentration by CHG application strategy. Note. *18.75 μg/mL, **128 μg/mL.

.02, respectively). To control for ease of CHG application based on
surgical site, skin CHG data were also stratified by surgical site;
however, there were no statistically significant differences.
Discussion
Daily bathing with CHG is an effective intervention for reducing
microbial density on skin and is recommended by the CDC as a
preoperative strategy to reduce the risk of a SSI.2,3 Many studies
have compared 2% CHG-impregnated cloths to 4% CHG liquid
applications, but few have assessed the latter’s ability to achieve
CHG skin concentrations for reducing microbial density of
gram-positive bacteria and the risk of contamination with
KPC-producers by half.5,6 Results from our study suggest that
bathing with 4% CHG for more consecutive days provides higher
levels CHG skin concentration on the day of surgery and those levels are more frequently at or above key CHG skin concentration
thresholds.
Our findings could be related to either a CHG build-up effect on
the skin or patients improving their ability to apply CHG with
more applications. Our data are consistent with other assessments
of 4% CHG liquid application methods. Rhee et al7 reported that
two 4% application methods resulted in CHG skin concentrations
of 58.6 and 156.3 μg/mL 6 hours after bathing.
Our study has several limitations. Enrolled patients were not
randomized to arms of the study. In addition, we did not review
clinical outcomes of the enrolled patients due to small sample size.

References
1. Zimlichman E, Henderson D, Tamir O, et al. Health care–associated infections: a meta-analysis of costs and financial impact on the US Health Care
System: meta-analysis of health care–associated infections. JAMA Intern
Med 2013;173:2039–2046.
2. Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease
Control and Prevention guideline for the prevention of surgical site infection,
2017. JAMA Surg 2017;152:784–791.
3. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA.
Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med
2007;167:2073.
4. Davies GE, Martin JF a R, Rose FL, Swain G. 1: 6-DI-4’-chlorophenyldiguanidohexane (“ HIBITANE”*): laboratory investigation of a new antibacterial
agent of high potency. Brit J Pharmacol 1954;9:192–196.
5. Lin MY, Blom DW, Hayden MK, et al. The effectiveness of routine daily
chlorhexidine gluconate bathing in reducing Klebsiella pneumoniae carbapenemase–producing Enterobacteriaceae skin burden among long-term acutecare hospital patients. Infect Control Hosp Epidemiol 2014;35:440–442.
6. Popovich KJ, Lyles R, Hayes R, et al. Relation of chlorhexidine gluconate skin
concentration to microbial density on skin of critically ill patients bathed
daily with chlorhexidine gluconate. 2013;33:889–896.
7. Rhee Y, Palmer LJ, Okamoto K, et al. Differential effects of chlorhexidine skin
cleansing methods on residual chlorhexidine skin concentrations and bacterial recovery. Infect Control Hosp Epidemiol 2018;39:405–411.
8. Ritz J, Pashnik B, Padula C, Simmons K. Effectiveness of 2 methods of
chlorhexidine bathing. J Nurs Care Qual 2012;27:171–175.
9. Rhee Y, Hayden MK, Simms A, et al. Impact of measurement and results
feedback of chlorhexidine gluconate (CHG) skin concentrations in medical
intensive care unit (MICU) patients receiving CHG bathing. Open Forum
Infect Dis 2019;6 suppl 2:766–767.

Downloaded from https://www.cambridge.org/core. 07 Oct 2020 at 21:13:37, subject to the Cambridge Core terms of use.

